Answers are grounded in this paper and cite their sources.
It is well established that even small changes in amino acid side chains of antigenic peptide bound to major histocompatibility complex (MHC) protein may completely abrogate recognition of the peptide-MHC (pMHC) complex by the T cell receptor (TCR). Often, however, several nonconservative substitutions in the peptide antigen are accommodated and do not impair its recognition by TCR. For example, a preponderance of natural sequence variants of the human immunodeficiency virus p17 Gag-derived peptide SLYNTVATL (SL9) are recognized by cytotoxic T lymphocytes, which implies that interactions with SL9 variants are degenerate both with respect to the class I MHC molecule and with respect to TCR. Here we study the molecular basis for this degenerate recognition of SL9 variants. We show that several SL9 variants bind comparably well to soluble HLA-A2 and to a particular soluble TCR and that these variants are active in the cognate cytotoxicity assay. Natural SL9 variation is restricted by its context in the HIV p17 matrix protein. High resolution crystal structures of seven selected SL9 variants bound to HLA-A2 all have remarkably similar peptide conformations and side-chain dispositions outside sites of substitution. This preservation of the peptide conformation despite epitope variations suggests a mechanism for the observed degeneracy in pMHC recognition by TCR and may contribute to the persistence of SL9-mediated immune responses in chronically infected individuals. It is well established that even small changes in amino acid side chains of antigenic peptide bound to major histocompatibility complex (MHC) protein may completely abrogate recognition of the peptide-MHC (pMHC) complex by the T cell receptor (TCR). Often, however, several nonconservative substitutions in the peptide antigen are accommodated and do not impair its recognition by TCR. For example, a preponderance of natural sequence variants of the human immunodeficiency virus p17 Gag-derived peptide SLYNTVATL (SL9) are recognized by cytotoxic T lymphocytes, which implies that interactions with SL9 variants are degenerate both with respect to the class I MHC molecule and with respect to TCR. Here we study the molecular basis for this degenerate recognition of SL9 variants. We show that several SL9 variants bind comparably well to soluble HLA-A2 and to a particular soluble TCR and that these variants are active in the cognate cytotoxicity assay. Natural SL9 variation is restricted by its context in the HIV p17 matrix protein. High resolution crystal structures of seven selected SL9 variants bound to HLA-A2 all have remarkably similar peptide conformations and side-chain dispositions outside sites of substitution. This preservation of the peptide conformation despite epitope variations suggests a mechanism for the observed degeneracy in pMHC recognition by TCR and may contribute to the persistence of SL9-mediated immune responses in chronically infected individuals. Antigen-specific receptor on T lymphocytes (TCR) 5The abbreviations used are: TCR, T cell receptor; MHC, major histocompatibility complex; pMHC, peptide-MHC complex; r.m.s.d., root mean square deviation; SL9, HIV Gag-derived peptide SLYNTVATL; HIV, human immunodeficiency virus; CTL, cytotoxic T lymphocytes; MES, 4-morpholineethanesulfonic acid; PBS, phosphate-buffered saline. recognizes a composite ligand consisting of antigenic peptide and MHC moiety (pMHC). Originally thought to be completely selective for a given pMHC complex, each TCR is now known to recognize a variety of natural pMHC ligands. For example, cytotoxic T lymphocytes (CTL) from the majority of HIV-infected patients recognize a specific Gag-derived peptide in the context of HLA-A2 class I MHC protein (1.Goulder P.J. Sewell A.K. Lalloo D.G. Price D.A. Whelan J.A. Evans J. Taylor G.P. Luzzi G. Giangrande P. Phillips R.E. McMichael A.J. J. Exp. Med. 1997; 185: 1423-1433Crossref PubMed Scopus (172) Google Scholar, 2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). The presented peptide includes residues 77–85 of p17, the matrix protein encoded by the gag gene. In canonical B-clade viruses such as HxBc2, this is a nonamer with the sequence SLYNTVATL, hence SL9. Some 64 sequence variants of the SL9 epitope have been identified among the sequenced M-group HIV-1 isolates (HIV sequence data base, hiv-web.lanl.gov), and many SL9-specific CTL clones from infected individuals recognize the majority of these variants with very few exceptions (3.Yang O.O. Sarkis P.T. Ali A. Harlow J.D. Brander C. Kalams S.A. Walker B.D. J. Exp. Med. 2003; 197: 1365-1375Crossref PubMed Scopus (118) Google Scholar), albeit with different sensitivity (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). This indicates that most amino acid substitutions in the SL9 epitope, which result from virus mutations, do not abolish the recognition of the pMHC complexes by the TCR. To investigate the basis of degenerate recognition of the HIV Gag epitope by CTL, we analyzed the interaction between soluble TCR from the SL9-specific CTL clone D3 and soluble HLA-A2 protein loaded with SL9 variants as an oligomeric complex and solved high resolution crystal structures of seven SL9 peptide variants bound to HLA-A2. The analysis revealed remarkably similar tertiary structures for all MHC-bound peptides. Importantly, this common conformation was distinct from that of other HLA-A2-bound peptides. This uniquely conserved structure of the peptides and the nature of amino acid residues at critical peptide positions regardless of other natural substitutions suggest a mechanism for the observed degeneracy in recognition. Proteins and Enzyme-linked Immunosorbent Assay—Expression and purification of soluble D3 TCR and HLA-A2-containing site for biotinylation were performed as described (4.Anikeeva N. Lebedeva T. Krogsgaard M. Tetin S.Y. Martinez-Hackert E. Kalams S.A. Davis M.M. Sykulev Y. Biochemistry. 2003; 42: 4709-4716Crossref PubMed Scopus (46) Google Scholar, 5.Anikeeva N. Lebedeva T. Sumaroka M. Kalams S.A. Sykulev Y. J. Immunol. Methods. 2003; 277: 75-86Crossref PubMed Scopus (17) Google Scholar). The HLA-A2 was biotinylated using biotin transferase (avidity) according to the manufacturer's protocol, and the HLA-A2-peptide/tetramer was produced as described (6.Altman J. Moss P. Goulder P. Barouch D. McHeyzer-Williams M. Bell J. McMichael A. Davis M. Science. 1996; 274: 94-96Crossref PubMed Scopus (3155) Google Scholar, 7.Crawford F. Kozono H. White J. Marrack P. Kappler J. Immunity. 1998; 8: 675-682Abstract Full Text Full Text PDF PubMed Scopus (413) Google Scholar) using a streptavidin-peroxidase conjugate (Sigma). Binding of various peptide-HLA-A2 complexes to soluble D3 TCR was evaluated as described previously (4.Anikeeva N. Lebedeva T. Krogsgaard M. Tetin S.Y. Martinez-Hackert E. Kalams S.A. Davis M.M. Sykulev Y. Biochemistry. 2003; 42: 4709-4716Crossref PubMed Scopus (46) Google Scholar, 5.Anikeeva N. Lebedeva T. Sumaroka M. Kalams S.A. Sykulev Y. J. Immunol. Methods. 2003; 277: 75-86Crossref PubMed Scopus (17) Google Scholar). Briefly, 96-well plates were coated with soluble TCR at 12 μg/ml at 4 °C overnight and blocked with 1% bovine serum albumin/PBS for 2 h at room temperature. Peptide-HLA-A2 tetramers were diluted in 1% bovine serum albumin/PBS and added to the plates in triplicate at various concentrations. The excess of the peptide (about 10–5 m) was kept in solution to ensure saturation of HLA-A2 molecules. After 2 h of incubation at room temperature, the plates were washed three times with iced PBS/Tween and cold PBS, and the assay was developed with o-phenylenediamine; the absorbance was measured at 490 nm. For crystallization purposes, the biotin-receptive site was deleted, and the HLA-A2 was expressed, purified, and loaded with peptides as above. Cells and Cytolytic Assay—The CD8+ HIV Gag-specific D3 CTL and the HLA-A2+ Epstein-Barr virus-transformed B cell line JY were maintained in culture as described (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). 51Cr-Labeled JY cells (5 × 103 cell/well) were incubated in triplicate with designated dilutions of peptides in complete medium in the presence of D3 CTL at a CTL/target cell ratio of 5:1 in 96-well round bottom plates. Control wells containing either 51Cr-labeled JY cells and CTL without peptide or with irrelevant peptide or the labeled cells in the presence of detergent or medium alone were prepared and carried out in quadruplicate. After 4 h at 37°C under 5% CO2, 100-μl aliquots from each supernatant were counted on a γ-counter (Wallac), and percent specific lysis was determined as described previously (51Cr release into supernatant – spontaneous release)/(total release in detergent – spontaneous release) × 100 (8.Sykulev Y. Vugmeyster Y. Brunmark A. Ploegh H. Eisen H. Immunity. 1998; 9: 475-483Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar). Crystallization—Orthorhombic crystals of the HLA-A2-SL9 complex were grown by the hanging-drop method at 20 °C by suspending 2 μl of 10 mg/ml protein mixed with 2 μl of 1.6 m (NH4)2SO4, 10 mm CoCl2, and 100 mm MES, pH 6.5. The monoclinic crystals were prepared by microseeding. The seeding solutions were prepared by crushing the orthorhombic crystals with a glass rod and serially diluting this mixture with a buffer containing 15% polyethylene glycol 6000 and 25 mm MES, pH 6.5. The monoclinic crystals were grown by the hanging-drop method at 20 °C by suspending 2 μl of 10 mg/ml protein mixed with an equal volume of the seeding solution. The drops were equilibrated over a reservoir buffer containing 15% polyethylene glycol 6000 and 25 mm MES, pH 6.5. Crystals reached the maximum size (SL9-HLA-A2, 300 × 200 × 20 μm) within 1–2 days. Data Collection and Processing—The orthorhombic crystals were transferred into cryoprotectant buffer containing 1.6 m (NH4)2SO4, 10 mm CoCl2, 100 mm MES, pH 6.5, 20% glycerol, and 10% ethylene glycol, pH 6.5. Monoclinic crystals were transferred into cryoprotectant buffer containing 20% polyethylene glycol 6000, 25 mm MES, 0.02% NaN3, and 20% glycerol, pH 6.5. All crystals were frozen at 100 K in cold nitrogen. Diffraction data for all complexes were collected on beamline X4A at the National Synchrotron Light Source (Brookhaven, NY) using a Quantum 4 charge-coupled device (Area Detector Systems Corp., Poway, CA). Diffraction data were processed with DENZO and SCALEPACK (9.Minor W. Cymborowski M. Otwinowski A. 101: Scopus Google Scholar). Data are in and structure of complex in the orthorhombic was determined by molecular in P. J. M. T. 1998; PubMed Scopus Google Scholar) using as the Immunity. Full Text Full Text PDF PubMed Scopus Google Scholar). The structure of the monoclinic crystal was solved by molecular using the orthorhombic HLA-A2 in the orthorhombic is that by P.J. B. PubMed Scopus Google Scholar, P.J. B. PubMed Scopus Google Scholar), the monoclinic is despite cell W. A. M. J. PubMed Scopus Google Scholar). All other monoclinic complexes were determined by using the monoclinic HLA-A2 structure as a In all peptides were added to HLA-A2 by into and was used at the of to was performed with the M. A. PubMed Scopus Google Scholar). The for all structures are presented in have been in the Data and Data with the are in of and we complexes using the W. H. D. J. PubMed Scopus Google Scholar). we to residues that of the which the of the residues and We determined the and for the peptide using the 1996; PubMed Scopus Google Scholar). of SL9 and Natural by D3 known natural SL9 the most at of and substitutions at other peptide and substitutions are for at and are very few of for at or for at the residues and substitutions are as in to for at and for at for at for at and for at acid residues at positions and the TCR Immunity. Full Text Full Text PDF PubMed Scopus Google Scholar, Full Text PDF PubMed Scopus Google Scholar, P. 1996; PubMed Scopus Google Scholar) and CTL recognition. We have on SL9 and of its natural which for of the HIV-1 The majority of the SL9 natural variants were active in the cytotoxicity assay (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). was a of for in which not peptide to HLA-A2 completely CTL recognition that a critical in recognition of the complex by D3 TCR. The natural was active SL9 and of natural and SL9 variants by SL9-specific D3 of natural and SL9 variants by SL9-specific D3 in the medium that is to lysis of JY cells by D3 that is to of peptide to soluble HLA-A2 by or to by the of CTL irrelevant of is by the of pMHC complexes in the of the were previously (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google were in the peptide assay (8.Sykulev Y. Vugmeyster Y. Brunmark A. Ploegh H. Eisen H. Immunity. 1998; 9: 475-483Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar) using SL9 as a indicates not in the medium that is to lysis of JY cells by D3 that is to of peptide to soluble HLA-A2 by or to by the of CTL irrelevant of is by the of pMHC complexes in the of the were previously (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). were in the peptide assay (8.Sykulev Y. Vugmeyster Y. Brunmark A. Ploegh H. Eisen H. Immunity. 1998; 9: 475-483Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar) using SL9 as a indicates not We variants with at other The variants with nonconservative substitutions of for at and for at were not recognized by the TCR and It is to that SL9 natural variants have substitutions at in this which to in p17, to be conserved in all known was from SL9, was the peptide in which was for at very peptide all three substitutions was not active at all and other data (3.Yang O.O. Sarkis P.T. Ali A. Harlow J.D. Brander C. Kalams S.A. Walker B.D. J. Exp. Med. 2003; 197: 1365-1375Crossref PubMed Scopus (118) Google Scholar) suggest that to peptide recognition by the TCR. of D3 TCR with with Natural SL9 interactions between HLA-A2 loaded with SL9 variants and D3 TCR were evaluated in an assay in which pMHC tetramers are for to soluble D3 on the (4.Anikeeva N. Lebedeva T. Krogsgaard M. Tetin S.Y. Martinez-Hackert E. Kalams S.A. Davis M.M. Sykulev Y. Biochemistry. 2003; 42: 4709-4716Crossref PubMed Scopus (46) Google Scholar, 5.Anikeeva N. Lebedeva T. Sumaroka M. Kalams S.A. Sykulev Y. J. Immunol. Methods. 2003; 277: 75-86Crossref PubMed Scopus (17) Google Scholar). The of for was used to the of each a is with a tetramers containing peptides with at not bind D3 TCR to a the of at in the of the and to be critical for of these amino with completely in other peptide positions either a small or not at all of HLA-A2 with SL9 and and of the pMHC complexes recognized by SL9-specific TCR, we determined the crystal structures of the and complexes to between and The structures of the MHC are as are the conformations of SL9 and the variants of in different in the peptide that the observed peptide conformation is not an of crystallization the conformation of the peptide bound to the MHC All peptide structures peptide side chains at positions and were for the SL9 peptide is in the of the at from the and with and for recognition by the TCR. of the with at to the of a with in the complex in the complex, of the at with to the of a different in of the of the nature of and of the by may have an on the interaction (4.Anikeeva N. Lebedeva T. Krogsgaard M. Tetin S.Y. Martinez-Hackert E. Kalams S.A. Davis M.M. Sykulev Y. Biochemistry. 2003; 42: 4709-4716Crossref PubMed Scopus (46) Google Scholar, Immunity. Full Text Full Text PDF PubMed Scopus Google Scholar), the complete of of and to D3 TCR In the of these in the and structures to the and at a the peptide a the of changes of pMHC that may TCR recognition. of SL9 and variants bound to HLA-A2 is in The of the peptides is to similar to other peptide-MHC class I structures Full Text PDF PubMed Scopus Google Scholar, M. Science. PubMed Scopus Google Scholar), as by the of the peptide in positions and in and The of SL9 side chains as bound to HLA-A2 is in The and side chains show in and the nonconservative of for to a complete of the the of this and other SL9 peptides are of the of to the of peptide conformation in recognition of the SL9 of we the structure of the SL9 peptide with the structures of other peptides bound to HLA-A2 Immunity. Full Text Full Text PDF PubMed Scopus Google Scholar, P.J. B. PubMed Scopus Google Scholar, W. A. M. J. PubMed Scopus Google Scholar, Full Text PDF PubMed Scopus Google Scholar, P. 1996; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, M. H. K. D. 1998; PubMed Scopus Google Scholar, Y. K. D. W. D. Immunity. 1998; 8: Full Text Full Text PDF PubMed Scopus Google Scholar, R. E. J. Exp. Med. PubMed Scopus Google Scholar, J.A. J. 274: Full Text Full Text PDF PubMed Scopus Google Scholar, S. J. 274: Full Text Full Text PDF PubMed Scopus Google Scholar, P. J. Immunol. PubMed Scopus Google Scholar, P. P. M. J. Immunol. PubMed Scopus Google Scholar, R. D. Ploegh S. A. PubMed Scopus Google Scholar, J. D. J.A. E. J. Immunol. 2003; PubMed Scopus Google Scholar). the of we used the for at each peptide The variations between SL9 and SL9 variants were with between SL9 and other HLA-A2 peptides SL9 to the natural and variants we the structures of the peptides to be very in for each The residues at the and of the peptide are of and the is the of this is In of the structure of SL9 to the structures of other complexes revealed the peptide at the with of The reached specific of and at peptide positions and the for most peptide residues between SL9 variants and other for SL9 at and are from the data that the conformation common to all SL9 variants is distinct from that in other peptides bound to HLA-A2. for the SL9 and for TCR SL9 conformation is distinct from other peptides at the and the side chains at these positions do not the conformation and substitutions are accommodated without The side chains at and be of we the conformation with and with or and the structure with or variants that are known to bind HLA-A2 (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). It that a of to the conformation of SL9 variants in complex with HLA-A2. The conformation at and that are particular to the of SL9. For example, the at are uniquely that this and be an from a TCR of the SL9 conformation among SL9 variants interactions that may in these pMHC of the SL9 in the of the p17 the of natural variation of residues critical for TCR we analyzed the SL9 peptide in the context of the structure of the HIV matrix protein p17 D. S. A. 1996; PubMed Scopus Google Scholar). The SL9 peptide is within a which the p17 structure is to all other structure that to the SL9 of this and are completely and is between three and and in 4 and in and in the of and is in its The of the SL9 in the of p17 an for the of the the to the this may be into an or The for complete of in all known HIV and immunodeficiency virus isolates is not from the p17 the of SL9 in in p17 on its and may be from other of the gene. TCR on T cells is selected in the as a result of its by or MHC in with peptides from PubMed Scopus Google Scholar, Ploegh S. Full Text PDF PubMed Scopus Google Scholar, J. Exp. Med. PubMed Scopus Google Scholar). T cells do not to such to a peptide from a protein that is not produced in the In T cells recognize MHC from other individuals of the MHC J. Exp. Med. PubMed Scopus Google Scholar). that TCR recognize distinct pMHC It been that the of different by the TCR be as high as D. Immunol. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). a TCR bind to different pMHC is that the TCR its conformation in to to several different It been that the TCR is and changes to a cognate pMHC complex K. M. M. P. Science. 1998; PubMed Scopus Google Scholar, Davis M.M. S. A. PubMed Scopus Google Scholar, B. G. J. J. Bell J. B. P. Immunity. Full Text Full Text PDF PubMed Scopus Google Scholar, M. N. Davis M.M. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). which the of to TCR been (4.Anikeeva N. Lebedeva T. Krogsgaard M. Tetin S.Y. Martinez-Hackert E. Kalams S.A. Davis M.M. Sykulev Y. Biochemistry. 2003; 42: 4709-4716Crossref PubMed Scopus (46) Google Scholar). changes in the TCR structure that recognition of various are the is the of variations in the of pMHC complexes that be accommodated by a The of to pMHC variation is to recognition of virus by T an for J.A. J.D. Immunol. PubMed Scopus Google Scholar). HIV, to changes in changes within T cell may to from immune P. E. C. N. J.D. Wolinsky A. PubMed Scopus Google Scholar). changes do not epitope recognition and the persistence of T cell (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar, J. Immunol. Google Scholar). on high resolution crystal structures and we suggest that degeneracy in recognition of by D3 TCR is accommodated by a common of for all MHC-bound SL9 variants. We that all peptide variants conformations to HLA-A2 despite to three amino acid changes in the This which is distinct from that of other HLA-A2-bound is such that several is sensitivity to natural substitutions at which is the most in the pMHC complex, variants recognition at and the other major sites of to TCR. a distinct conformation for the natural SL9 G. T. K. K. Jones McMichael A.J. J. Exp. Med. PubMed Scopus Google Scholar). This peptide with to HLA-A2 SL9 is active in the CTL assay of and complexes to TCR is by similar and G. T. K. K. Jones McMichael A.J. J. Exp. Med. PubMed Scopus Google Scholar), is that SL9 and similar conformations recognition by the TCR G. T. K. K. Jones McMichael A.J. J. Exp. Med. PubMed Scopus Google Scholar), the of have that the conformation of a peptide from Epstein-Barr virus bound to not MHC is for peptide D. J. J. J. J. Exp. Med. PubMed Scopus Google Scholar) of the critical of the peptide conformation in recognition by TCR. Natural variation in the SL9 peptide is restricted by the critical of this peptide in the Gag protein in the SL9 of p17 to of the p17 structure and the and of the virus Y. Jones J. 1998; PubMed Google Scholar). The by of the p17 structure may in the peptide conformation of variants as bound to HLA-A2. recognition of SL9 by D3 TCR this however, variants that with or are recognized by D3 TCR The mechanism of degenerate recognition of the HIV Gag epitope described to be very different from that for recognition of virus peptide from the protein McMichael A.J. Bell Jones 2003; Scopus Google Scholar), a common epitope for all virus It been that a the CTL which is very different from recognition of HIV several CTL clones comparably well (2.Brander C. Hartman K. Trocha A. Jones N. Johnson R. Korber B. Wentworth P. Buchbinder S. Wolinsky S. Walker B. Kalams S. J. Clin. Investig. 1998; 101: 2559-2566Crossref PubMed Scopus (146) Google Scholar). different of degenerate recognition of protein and SL9 pMHC complexes are to contribute to CTL these the described degeneracy in recognition of SL9 is determined by for virus persistence of CTL responses may on the nature of the antigen and to a on the of T cells in infected This the for peptide as natural do not J.D. J.A. J. Clin. Investig. PubMed Scopus Google Scholar). In a p17 Gag containing to SL9-specific CTL in individuals G. W. J. Jones P. Buchbinder S. J. J. Immunol. PubMed Scopus Google Scholar) with the of such CTL the of the the majority of with HIV have a SL9, of this peptide and of is thought to be for the of SL9-specific The of J.D. T. J.A. S. A. 1997; PubMed Scopus Google Scholar) in to a of and T CTL, to HIV X4A at the National Synchrotron Light a of was by the with
No takes yet. Share an insight, caveat, or question.
Martı́nez-Hackert et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: